Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by MAIA Biotechnology, Inc.
< Previous
1
2
Next >
FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma
November 10, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIO
November 07, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Reveals Higher Anticancer Potency of Telomere-Targeting Compounds Derived from THIO
October 30, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial
October 24, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology to Present Preliminary Safety and Efficacy Data from THIO-101 Phase 2 Clinical Trial at European Society for Medical Oncology Congress 2023
October 19, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology to Present Latest Findings for Second Generation THIO Program at Turkish Biochemical Society’s International Biochemistry Congress 2023
October 17, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Reveals New Data Showing THIO’s Potent Anticancer Activity in Aggressive Pediatric Brain Cancer
October 12, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Accelerates Enrollment in THIO-101 Phase II Clinical Trial as Efficacy Is Observed in Dosed Patients
October 10, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Announces Potent Anticancer Activity of THIO in Gliomas
October 10, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Announces FDA Clearance of IND Application for THIO, a First-in-Class Telomere Targeting Agent for the Treatment of Non-Small Cell Lung Cancer
October 03, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Announces Share Repurchase Program
September 28, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Reports Second Quarter 2023 Financial Results and Provides Updates for THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
August 08, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Reports Updates on Disease Control Rates for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer
July 11, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Reports Updates on Preliminary Survival Data for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer
July 10, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Announces Updates in Enrollment in Phase II Clinical Trial: THIO-101 Has Enrolled 29 Patients
June 20, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Files Second Patent For New Telomere-Targeting Molecules Program
June 07, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 08, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology, Inc. Announces Closing of Public Offering
April 27, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology, Inc. Announces Pricing of Public Offering
April 24, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Reports Preliminary Survival Data in Part A of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
April 20, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Announces Excellent Efficacy of THIO in Liver Cancer Models
April 18, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology to Present at AACR Annual Meeting 2023
April 12, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Reports Positive Topline Data from Part A Safety Lead-In of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
April 11, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Reports Full Year 2022 Financial Results and Provides Corporate Update
March 24, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Announces No Exposure to Silicon Valley Bank
March 13, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Doses First Patients in Europe in Ongoing Phase 2 Trial (THIO-101) Evaluating THIO for Non-Small Cell Lung Cancer Treatment
March 07, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
ADDING MULTIMEDIA: MAIA Biotechnology’s Telomere-targeting Agent THIO, in Combination With Checkpoint Inhibitor Immune Therapies Atezolizumab (anti-PD-L1) or Pembrolizumab (anti-PD-1), Demonstrated Significantly Greater Tumor Inhibition
February 13, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Advances New Telomere-Targeting Molecule Program
January 17, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology to Participate in Four Upcoming Investor Conferences
January 05, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
MAIA Biotechnology Holds Successful Pre-IND Meeting with FDA for Planned US Expansion of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
December 20, 2022
From
MAIA Biotechnology, Inc.
Via
Business Wire
Tickers
MAIA
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.